| abstract |
The present invention relates to a series of fused pentacyclic imidazole derivatives which are potent modulators of human TNFα activity and thus have the benefit of treating and/or preventing various human diseases, including autoimmune and inflammatory conditions; neurological and neurodegenerative disorders. Conditions; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; eye diseases; and carcinogenic disorders.nIn particular, the present invention relates to 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]diazocin-5 ( 14H)-keto derivatives and analogs thereof. |